Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE^® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

“The combination, which was generally well tolerated, provided durable benefit even in patients with adverse cytogenetics, as well as in both younger and older patients. It may also delay the need for transplant in some patients, although larger randomized trials are needed to confirm these findings.”

"We are seeing increasing interest from physicians to explore ways to optimize multiple myeloma treatment combinations using VELCADE as a foundation of myeloma therapy, across a broad spectrum of patients," said Nancy Simonian, M.D., Chief Medical Officer, Millennium.